The Food and Drug Administration is warning health care providers and the public not to use two COVID-19 antigen and antibody tests, due to high risk of false results. The FDA has not authorized or approved the two tests — Lepu Medical Technology’s SARS-CoV-2 Antigen Rapid Test Kit and the Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography) — in the U.S., but the agency is aware that these tests were distributed to some pharmacies to be sold for at-home testing and sold directly to consumers. Health care providers should consider re-testing with a different SARS-CoV-2 antibody test any patients who were suspected to have had recent or prior COVID-19 infection and were tested with either of the two tests in question.

Related News Articles

Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…